Menactra® helps protect against invasive meningococcal disease (IMD)
Menactra® is a vaccine used to help prevent invasive meningococcal diseases (IMD) caused by Neisseria meningitidis (serogroups A, C, Y, and W-135) in people 9 months to 55 years old.
Being a teen or young adult is a risk factor for IMD
Young adults are one of the most at-risk groups when it comes to invasive meningococcal disease.
Other risk factors include:
· Close direct contact with others
· Contact with infected saliva
· Spending time in crowded areas, like dorms
Student life is more complicated than ever. A vaccine to help protect against IMD is not.
The Menactra® vaccine is a simple precaution that provides protection against 4 strains of IMD (A, C, Y and W-135).
Menactra® helps protect against IMD
Menactra® helps your body to produce its own natural protection against four strains of Neisseria meningitidis that cause IMD.
Ask your healthcare provider about Menactra® —15+ years’ experience.
Possible side effects to know about
A vaccine, like any medicine, may cause serious problems, such as severe allergic reactions. The risk of Menactra® causing serious harm is extremely small. The small risks associated with Menactra® are much less than the risks associated with getting the disease.
Tell your doctor, nurse or pharmacist as soon as possible if you do not feel well after having Menactra®.
Serious side effects are extremely rare.
Some people who receive Menactra® may have side effects such as redness or pain at the site of injection, headache or fever, that in majority are mild in intensity.
Common side effects in infants include:
loss of appetite
These side effects usually go away within a few days. This is not a complete list of side effects.
For any unexpected effects while taking Menactra®, contact your doctor or pharmacist.
Ask your healthcare practitioner about the
Use the following questions to find out more from your doctor or pharmacist:
- Am I at risk for IMD? If so, what should I do?
- What are my options to help prevent IMD as a teen or young adult?
- What are my options to help prevent IMD in my child?
Indication and safety information:
Menactra® is a vaccine that is used to prevent meningococcal diseases and/or septicemia (blood poisoning) caused by bacteria called Neisseria meningitidis (serogroups A, C, Y and W-135). This vaccine may be given to persons 9 months through 55 years of age. Menactra® is not indicated for the prevention of invasive meningococcal disease caused by serogroup B. Menactra® is not to be used for the treatment of invasive meningococcal disease, and cannot prevent complications or death after the onset of the disease. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS after receiving Menactra®. Persons with an allergy to any component of the vaccine or the container should not receive the vaccine. As with any vaccine, Menactra® may not protect 100% of vaccinated individuals. Adverse reactions and side effects may occur. The most common side effects in adolescents and adults (11-55 years old) were pain, induration, redness and swelling at the injection site, and headache, fatigue and malaise. Talk to your healthcare provider to see if Menactra® is right for you or a family member. For more information, visit www.sanofi.ca.